Table 1.
Baseline clinicopathological characteristics of patients
| Variable | Patients, n = 217 |
|---|---|
| Age (median-range) | 48 (20–67) |
| < 45 years | 130 (83.3%) |
| ≥ 45 years | 26 (16.7%) |
| ECOG PS | |
| 0–1 | 215 (99.1%) |
| 2 | 2 (0.9%) |
| Neoadjuvant chemotherapy | |
| Yes | 18 (8.3%) |
| No | 199 (91.7%) |
| Histologic subtype | |
| invasive ductal carcinoma | 208 (95.8%) |
| special types of invasive carcinoma | 3 (1.4%) |
| non-invasive breast neoplasms | 6 (2.8%) |
| Nottingham grade (n = 211, for invasive carcinoma) | |
| uncertain | 13 (6.2%) |
| Grade 1–2 | 131 (62.1%) |
| Grade 3 | 67 (31.7%) |
| Molecular subtype | |
| Luminal A | 32 (20.5%) |
| Luminal B | 101 (64.7%) |
| HR-negative/HER2-positive | 10 (6.4%) |
| HR-positive/HER2-positive | 2 (1.3%) |
| Triple-negative | 2 (1.3%) |
| TNM Stage at initial diagnosis | |
| uncertain | 34 (15.7%) |
| I | 85 (39.2%) |
| II | 98 (45.1%) |
| T at initial diagnosis | |
| uncertain | 20 (9.2%) |
| 1 | 110 (50.7%) |
| 2 | 87 (40.1%) |
| N at initial diagnosis | |
| uncertain | 14 (6.4%) |
| Negative | 151 (69.6%) |
| Positive | 52 (24.0%) |
| IORT dose | |
| low-dose (10 Gy) | 189 (87.1%) |
| intermediate-dose (> 10–<20 Gy) | 9 (4.1%) |
| high-dose (20 Gy) | 19 (8.8%) |
| Wound healing time after IORT | |
| ≤ 4 weeks | 207 (95.4%) |
| 4–8 weeks | 2 (0.9%) |
| > 8 weeks | 8 (3.7%) |
| Acute radiation dermatitis after WBI | |
| Grade 1–2 | 216 (99.5%) |
| Grade 3 | 1 (0.5%) |